(Q38958797)

English

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology

scientific article published on 24 May 2007

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

author name string

Sonya L Cyr

1

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Taff Jones

2

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Ioana Stoica-Popescu

3

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Angela Brewer

4

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sophie Chabot

5

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Michelle Lussier

6

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

David Burt

7

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Brian J Ward

8

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

language of work or name

0 references

publication date

24 May 2007

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

number of pages

12

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

5378-5389

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Neurotrophin overexpression in lower airways of infants with respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Aluminium compounds for use in vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Vaccine adjuvants: current state and future trends

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Molecular analysis of respiratory syncytial virus reinfections in infants from coastal Kenya

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Cellular immunity and lung injury in respiratory virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A novel and effective intranasal immunization strategy for respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A nasal Proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Protollin: a novel adjuvant for intranasal vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Purification and characterization of simian immunodeficiency virus (SIVmac) envelope glycoprotein gp130 from virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

The ins and outs of cross-presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Microparticle vaccine approaches to stimulate mucosal immunisation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Mucosal vaccines: the promise and the challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Cell-mediated adaptive immune defense of the lungs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Antigen-dependent proliferation and cytokine induction in respiratory syncytial virus-infected cotton rats reflect the presence of effector-memory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Cellular immunity and memory to respiratory virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.004

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.05.004

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38958797&oldid=1799140587"